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Abstract: The development of multicistronic vectors has opened up new opportunities to address the
fundamental issues of molecular and cellular biology related to the need for the simultaneous delivery
and joint expression of several genes. To date, the examples of the successful use of multicistronic
vectors have been described for the development of new methods of treatment of various human
diseases, including cardiovascular, oncological, metabolic, autoimmune, and neurodegenerative
disorders. The safety and effectiveness of the joint delivery of therapeutic genes in multicistronic
vectors based on the internal ribosome entry site (IRES) and self-cleaving 2A peptides have been shown
in both in vitro and in vivo experiments as well as in clinical trials. Co-expression of several genes in
one vector has also been used to create animal models of various inherited diseases which are caused
by mutations in several genes. Multicistronic vectors provide expression of all mutant genes, which
allows the most complete mimicking disease pathogenesis. This review comprehensively discusses
multicistronic vectors based on IRES nucleotide sequence and self-cleaving 2A peptides, including its
features and possible application for the treatment and modeling of various human diseases.
Keywords: 2A peptides; IRES; multicistronic constructs; gene therapy; neurodegenerative diseases;
metabolic diseases; cancer; autoimmune diseases; cardiovascular diseases
1. Introduction
Recently, gene therapy was introduced as having significant potential for the treatment of various
diseases. Gene therapy involves the modulation of target gene expression to achieve a therapeutic
effect [1]. From the beginning, gene therapy was mainly based on viral vectors, which met a lot of
skepticism in both the scientific and medical communities because of the unexpectedly high toxicity of
viruses [2]. However, with the advent of various gene therapeutic agents for the treatment of cancer [3],
blindness [4], immune [5] and neuronal disorders [6], renewed attention has been focused on gene
therapy. Many of the currently existing replication-defective viruses can carry large therapeutic genes,
efficiently transduce various types of cells, and provide long-term and stable expression of genes of
interest [7]. However, viral vectors can also be immunogenic or pathogenic, or can cause inflammation
or malignant transformation of infected cells [8].
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Other non-viral approaches for gene delivery, such as cationic lipids (liposomes and lipoplexes)
and polymers (polyplexes), have their advantages and disadvantages [9,10]. Non-viral delivery
methods are safer, lower immunogenic responses, as well as allowing the downloading and delivery
of bioactive molecules and genetic material of unlimited size [11].
Besides the question of delivery, gene therapy also faces challenges that require the delivery and
expression of several therapeutic agents at once. Cloning of several genes into one vector greatly
facilitates the implementation of many fundamental tasks, and the joint expression (co-expression) of
many genes improves the effectiveness of gene therapy. Examples of this include co-expression of a
gene of interest with a reporter gene for the rapid identification and selection of modified cells [12],
co-expression of several subunits of one protein [13,14], several proteins, for example, for the delivery of
enzyme complexes [15,16], and transcription factors [17,18], or several therapeutic agents in combined
gene [19,20] or gene and cell therapy [21–25]. Co-expression of several genes in one vector is also used
to create animal models of various hereditary diseases caused by mutations in several genes rather
than just one. These vectors provide expression of all mutant genes, which allows mimicking disease
pathogenesis to the greatest possible extent [26,27]. Various molecular strategies are used for the
simultaneous expression of several genes in one vector, including the use of multiple promoters [28],
signals of splicing [29], fusion of genes [30] and cleavage factors [31,32]. The use of multiple promoters
suggests an existence of several independent transcription units, each of which has its own promoter
and open reading frame (ORF) [33]. The use of different promoters is suitable when simultaneous but
not sequential gene expression is important. These kinds of plasmids containing several genes under
different promoters are also used in gene expression profiling studies [34]. However, the combined use
of multiple promoters can result in the transcriptional interference of the downstream promoter and
the suppression or stimulation of the transcriptional process [35].
Another strategy is to insert splicing signals before and after the first gene of interest. As a
result, several mature mRNAs can be produced by splicing a single pre-mRNA. There are several
transcriptional units in this variant, which provide independent gene expression; however, there are
risks of splicing and rearrangement changes during vector construction [36]. Such vectors have their
advantages; for example, there is an alternative-splicing-based bicistronic vector in which the ratio
between the synthesized proteins can be controlled by changing the consensus sequence. This vector
has been successfully used for the production of recombinant monoclonal antibodies [29].
Gene fusion is mostly used to attach the gene of interest with a reporter gene [37]. In this case,
the expression of genes is controlled by one promoter and results in a hybrid protein, which may
affect its functions [38]. Insertion of proteolytic cleavage sites between genes is also used. The use of
this strategy is limited however, because the protease and protein have to be localized in the same
subcellular space [31].
Among all of the strategies used to construct vectors containing two or more genes, the most
promising and widely used approaches presently are the use of internal ribosome entry site (IRES) and
self-cleaving 2A peptides, since these methods can overcome many of the disadvantages occurring
in the above strategies. Vectors encoding the nucleotide sequences of IRES or 2A peptides are called
multicistronic vectors, since they simultaneously express two or more separate proteins from the
same mRNA unlike other vectors [12]. This review discusses the mechanisms of IRES-based and 2A
peptide-based protein synthesis and their features and compares them with each other. The perspectives
about the use of IRES and 2A peptides to create multicistronic vectors for gene and gene and cell
therapy and the prevention of various human diseases are also discussed.
2. IRES
It is known that protein translation can occur cap-dependently or cap-independently. Most
often, in the initiation of translation in eukaryotes, the cap which binds to the small (40S) subunit
of ribosome and many translation initiation factors (eIF) are required [39,40]. The IRES sequence
controls cap-independent protein synthesis. The IRES-dependent initiation of the translation occurs
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independently of the mRNA 5’-end and is therefore called an internal initiation of translation (Figure 1).
The IRES sequence, like the 2A peptides, was first discovered in viruses [41]. IRES was initially found
to translate viral proteins; however, it was later determined that the initiation of translation of some
cellular genes can also be IRES-dependent [42–44].
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Table 1. Comparison of the characteristics of various strategies for the expression of multiple genes. 
Characteristic Properties of Protein 
Synthesis 
Size Gene Expression Level Cleavage 
IRES 
Ribosome dissociates when 
the synthesis of the first 
gene is complete, the 
synthesis is interrupted, a 
new translation initiation 
complex is assembled in the 
IRES region 
Large (over 
500 bp) 
The translation efficiency 
of the gene located 
downstream of the IRES 
is much lower than that 
of the gene located 
upstream of the IRES 
The resulting 
proteins are 
always separated 
from each other 
2A peptides 
Continuous synthesis of 
two proteins. Ribosomal 
skipping occurs after the 
synthesis of the first gene is 
complete, synthesis 
continues without the 
dissociation of ribosome 
Small (54–66 
bp) 
Better correlation of the 
expression of genes 
placed upstream and 
downstream of the 
peptide sequence 
Incomplete 
digestion of 
protein products 
is possible 
Multiple 
promoters 
Two separate transcription 
units, completely separated 
synthesis 
Large 
Poor correlation of the 
expression of two genes 
Independent 
products 
Splicing 
signals 
Two separate transcription 
units, completely separated 
synthesis 
Small 
Uncertain correlation of 
the expression of two 
genes 
Independent 
products 
Fusion of 
genes 
One chimeric polypeptide is 
translated, which can lead 
to impaired function 
No 
intermediate 
sequences 
Guaranteed 
co-expression 
Not cleaved 
product 
Cleavage 
factors  
Two proteins are translated 
together 
Small 
Guaranteed 
co-expression 
Cleaved by 
cellular proteases 
after protein 
synthesis 
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Figure 1. Comparison of the translation mechanism in i ternal ribosome entry site (IRES)-based and 2A
peptide-bas d multicistron c c structs. (a) In IRES-based constructs, translation i iti of each gene
occurs independently. IRES sequence controls cap-independent protein synthesis. The IRES-dependent
initiation of the translation occurs independently of the mRNA 5’-end. In the IRES region (like in the
cap region), ribosome binds with mRNA. The translation of the gene located upstream of the IRES
is cap-dependent, and that of the gene located downstream of the IRES is IRES-dependent. Thus,
the translation of two proteins located at the same mRNA is completely separated. (b) In constructs
with 2A peptide sequences, translation is initiated once, synthesis along mRNA occurs continuously;
however, during translation, the first peptide breaks from the second peptide in the 2A region. 2A
peptide cleavage site is located between glycine and proline. The cleavage process occurs inside the
ribosome during protein synthesis, the formation of a normal peptide bond between the amino acids is
inhibited only at the cleavage site, thus the cleavage does not affect the translation of the subsequent
protein, synthesis continues without the dissociation of ribosome. Theoretically, ribosomal skipping
provides complete cleavage of the final product; however, mechanism failures can occur. Ribosomal
skipping may not occur due to the inhibition of the cleavage reaction; in this case, fused products are
formed, or after the synthesis of the first polypeptide, the ribosome can drop off and then only the first
protein is synthesized.
The IRES-dependent initiation of translation in various viruses occurs in different ways. Due to
their specific structures, some IRESs can functionally replace many protein factors and, it is also
assumed, can bind and modify the ribosome conformation [45,46], which is why the IRES-dependent
initiation of translation does not require a complete (or any) eIF set. The eIF set depends on the
structure of IRES that varies in differing types of viruses [46]. All of the IRES types have complex
secondary and tertiary structures. IRES is a hinge molecule whose constituent elements can move
relative to each other. Conformational changes in IRES are necessary for the formation of the initiation
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complex; the greater the need for additional initiation factors, the more flexible the molecule [47].
The secondary structure of IRES from different viruses is comprehensively discussed in a previous
publication [45].
IRES is widely used to transfer several genes in multicistronic vectors, since it allows the expression
of several proteins from a single transcription unit. In the multicistronic vector, the first gene upstream
of IRES is translated in the cap-dependent manner, and in the downstream gene, translation initiation
is IRES-dependent (Figure 1). One of the significant disadvantages of such constructs is a decreased
IRES-dependent expression of the second gene [48]. The expression level of all IRES-dependent
proteins in one multicistronic vector is the same, regardless of the order of the genes. The translation of
all genes which are located downstream of the IRES occurs independently of each other [49], in contrast
to vectors containing 2A peptide sequences [32]. A significant advantage of IRES sequences is the
complete separation of proteins, whereas the use of 2A peptides can result in incomplete cleavage of
the translated polypeptide (Table 1) [50].
Table 1. Comparison of the characteristics of various strategies for the expression of multiple genes.
Characteristic Properties of Protein Synthesis Size Gene Expression Level Cleavage
IRES
Ribosome dissociates when the
synthesis of the first gene is
complete, the synthesis is
interrupted, a new translation
initiation complex is assembled in
the IRES region
Large (over 500 bp)
The translation efficiency of
the gene located downstream
of the IRES is much lower
than that of the gene located
upstream of the IRES
The resulting proteins are
always separated from
each other
2A peptides
Continuous synthesis of two
proteins. Ribosomal skipping
occurs after the synthesis of the
first gene is complete, synthesis
continues without the dissociation
of ribosome
Small (54–66 bp)
Better correlation of the
expression of genes placed
upstream and downstream of
the peptide sequence
Incomplete digestion of
protein products is possible
Multiple
promoters
Two separate transcription units,
completely separated synthesis Large
Poor correlation of the
expression of two genes Independent products
Splicing signals Two separate transcription units,completely separated synthesis Small
Uncertain correlation of the
expression of two genes Independent products
Fusion of genes
One chimeric polypeptide is
translated, which can lead to
impaired function
No intermediate
sequences Guaranteed co-expression Not cleaved product
Cleavage factors Two proteins aretranslated together Small Guaranteed co-expression
Cleaved by cellular proteases
after protein synthesis
3. Self-Cleaving 2A Peptides
Self-cleaving 2A peptides are promising candidates for the production of multicistronic vectors
due to their small size and self-cleavage ability. 2A peptides are composed of 16–20 amino acids and
originate from viral RNA. The most common 2A peptides used to produce multicistronic vectors are
F2A (2A peptide derived from the foot-and-mouth disease virus), E2A (2A peptide derived from the
equine rhinitis virus), P2A (2A peptide derived from the porcine teschovirus-1), and T2A (2A peptide
derived from the Thosea asigna virus) [51].
The mechanism of 2A peptide cleavage is also of interest. 2A peptides were first discovered in
1991 in the foot-and-mouth disease virus belonging to the Picornaviridae family. At that point, it
was suggested that the peptide could be cleaved by a protease encoded by the virus or an infected
cell; however, it later became clear that proteases are not involved in this process, and the cleavage
is mediated via a ribosomal skip mechanism [52,53]. It is known that proteins of picornaviruses
are encoded in one long open reading frame (ORF). The cleavage sites of these peptides are located
between the C-terminal glycine of 2A and the N-terminal proline of 2B (aminoacidic sequences of 2A
peptides are represented in a previous publication [54]). This process takes place inside the ribosome
during protein synthesis, the formation of a normal peptide bond between these amino acids at the
cleavage site is inhibited, but the cleavage does not affect the translation of the subsequent protein,
since ribosome dissociation does not occur (Figure 1) [55]. However, this mechanism can fail, in that
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ribosomal skipping sometimes does not occur and the protein synthesis continues which leads to the
formation of fused (uncleaved to each other) proteins. Sometimes, when the synthesis of a gene located
upstream of the 2A peptide sequence is completed, the ribosome drops off and translation stops, and
eventually only the first protein is synthesized. Despite such failures, 2A is the best way to provide
co-expression of several genes compared with other strategies [32].
Because of the incomplete cleavage of the products, the 2A-based multicistronic cassette can lead
to a decreased yield of the final product and to a protein dysfunction, and it therefore becomes necessary
to develop various ways in which to improve the cleavage of such structures. The formation of fused
products is believed to be due to the inhibition of the 2A cleavage reaction. The use of elongated 2A with
the additional spacers in the N-terminus of 2A peptide sequence can provide a solution, since it leads
to a decrease in the inhibition rate of the 2A cleavage reaction [56]. The insertion of additional spacer
sequences as well as the furin cleavage site are used for this purpose [57]. A glycine–serine–glycine
(GSG) spacer flexible linker sequence is most commonly used for the best cleavage [58–60]. In addition,
it was found that the order of various 2A peptide sequences in multicistronic constructs can also affect
the cleavage efficiency [32].
Liu et al. investigated the levels of gene expression downstream and upstream of the 2A peptide
sequence and the efficiency of protein cleavage in multicistronic vectors with different combinations of
2A peptides [32]. The authors showed a decrease in protein expression levels in the second position in
2A peptide-based bicistronic constructs. Interestingly, in tricistronic constructs the highest expression
is observed in the first position, then in the third, and the lowest expression in the second position,
although a gradual decrease in the amount of translated protein along the multicistronic vector is
expected. Researchers suggest that this may be due to the fact that T2A was used before the third gene,
and the P2A peptide sequence was used before the second gene. Thus, the use of different 2A peptides
can influence the expression levels of downstream proteins. A gradual decrease in the gene expression
from the first to the last is also observed in quadricistronic constructs. The authors observed that the
combination of 2A peptide sequences in the following order, namely T2A, P2A, and E2A, was optimal
when creating multicistronic vectors containing four genes [32]. Kim et al. compared the cleavage
efficacy of P2A, T2A, E2A, and F2A in different cell cultures, such as human cell lines, zebrafish
embryos, and adult mice liver. In all cell cultures, P2A showed the best cleavage efficiency [54].
The efficacy of using different 2A peptides for the production of monoclonal antibodies in the
Chinese hamster ovary (CHO) cell line was investigated by Yang et al. [57]. For this purpose, constructs
encoding the genes of the heavy and light chains of monoclonal antibodies, separated by different 2A
peptide sequences (F2A, E2A, P2A, and T2A) were produced. The use of such structures is important
for controlling the ratio of heavy and light chains. Different 2A peptides have shown differing cleavage
efficiencies and, consequently, differential monoclonal antibody yields, since the uncleaved polypeptide
products were removed. It has been shown that the use of any 2A peptide does not lead to complete
cleavage, but T2A showed the highest cleavage efficiency and level of product expression. The GSG
linker has also been shown to significantly increase 2A cleavage efficiency [58]. A study of the efficacy of
2A cleavage in Drosophila cell culture has also confirmed that T2A and P2A cleave most efficiently [61].
Thus, studies aimed at comparing the cleavage efficiency of 2A peptides have shown different
results, which can be associated with many factors, including experimental conditions and the use of
various cell cultures. However, most often the best result is shown by T2A and P2A [58–61]. In order
to identify the most suitable type of 2A for certain tasks and select the optimal conditions for using
each 2A, a comprehensive comparison and more detailed investigations of 2A are required.
The comparison of gene expression dynamics in multicistronic vectors containing IRES and P2A
peptide sequence has shown that P2A-based constructs provide more correlated gene expression than
IRES-based constructs in HEK293 cells (Table 1); however, no significant correlation was observed in
Neuro2a cells. These results confirm that IRES activity may vary depending on the cell type [62].
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4. Multicistronic Vectors for Neurodegenerative Disease Therapy
Neurodegeneration is characterized by the disturbance of structure and the loss of neuron function.
Many neurodegenerative disorders are caused by the accumulation and distribution of abnormal
protein aggregates in the central nervous system (CNS) [63]. Gene therapy may help overcome
the challenges of neurodegenerative disease treatment, including difficulties with the delivery and
distribution of therapeutic agents in the CNS, and multicistronic vectors enable the simultaneous
delivery and expression of several therapeutic genes.
The greatest success in the use of multicistronic vectors has been achieved in the treatment of
Parkinson’s disease (PD) characterized by selective loss of dopaminergic neurons in the substantia nigra
pars compacta (SNc), which leads to complete dopamine depletion and serious impairment of motor
functions (tremor, rigidity, akinesia, and other similar symptoms). Since the dopamine replacement
strategy is the most perspective strategy to treat PD [64], a lentiviral multicistronic construct encoding
genes of three proteins essential for dopamine biosynthesis, namely tyrosine hydroxylase (TH), aromatic
amino acid dopa decarboxylase (AADC) and GTP cyclohydrolase 1 (CH1) linked through IRES has
been proposed for restoring dopamine synthesis. Injection of this construct into the striatum of a PD
model (the 6-OHDA-lesioned rat striatum) in mice has led to the efficient transduction and long-term
gene expression, catecholamine production, and a significant decrease of apomorphine-induced motor
asymmetry [65]. In the same way, a bicistronic retroviral construct containing human TH and rat
GC genes, separated by IRES, and necessary for the synthesis of l-DOPA, the dopamine biosynthesis
intermediate product (3,4-dihydroxyphenylalanine), was produced. The efficiency of synthesis was
confirmed in mesenchymal stem cell (MSC) culture in vitro [66].
An experimental drug, ProSavin, can be considered the most efficient for the treatment of PD and is
intended for administration into the striatum of the patient’s brain. The drug is a viral vector encoding
AADC, TH, and CH1 genes, separated by IRES. Phase I/II clinical trials (numbers NTC00627588 and
NCT01856439; EudraCT numbers: 2007-001109-26 and 2009-017253-35) have shown that ProSavin
has a favorable safety profile and results in the improvement in the defined “off” Unified Parkinson’s
Disease Rating Scale part III motor scores after the injection into the striatum of PD patients [67].
Another therapeutic approach is the delivery of trophic factor genes, such as brain-derived
neurotrophic factor (BDNF), which has a neuroprotective function and regulates the transmission in
dopaminergic neurons in SNc, protecting SNc from 6-hydroxydopamine (6-OHDA). Delivery of the
BDNF gene as part of an adeno-associated virus (AAV)-based bicistronic vector co-expressing the
reporter gene of green fluorescent protein (GFP) through IRES resulted in a stable co-expression of
BDNF and GFP in SNc for nine months in vivo. Higher indices of motor functions (locomotor activity
and rotational activity) were observed in animals treated with BDNF compared to controls; however,
BDNF failed to affect nigrostriatal dopaminergic survival [68].
Some successes have also been achieved in the development of multicistronic vectors for the
treatment of amyotrophic lateral sclerosis (ALS) characterized by cholinergic dysfunction. The injection
of human umbilical cord blood mononuclear cells (hUCB-MCs) modified with an adenovirus encoding
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF2) linked through
P2A peptide sequence into an ALS mouse model led to the secretion of both growth factors in the
spinal cord, as well as the absence of immune response to 2A antigen after 28–52 days. Meanwhile,
the viability of xeno-transplanted cells remained at the same level in the spinal cord for one month [51].
Multicistronic vectors can also be used to produce transgenic animals for modeling human
neurodegenerative diseases, for example, Alzheimer’s disease (AD). Application of a retroviral vector
containing the amyloid precursor protein (APP), Tau protein (TAU), and human presenilin 1 (PS1)
genes with six well-characterized mutations, separated by 2A peptide sequence has allowed the
production of transgenic pigs with a high level of expression of APP, TAU, and PS1 in the animal
brain [26]. However, further studies are required to confirm the development of the pathogenesis of
AD in transgenic animals at the cellular, tissue, and body levels. It is of interest to create multicistronic
vector-based test systems for screening potential compounds for the treatment of neurodegenerative
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diseases. An example of such a test system is the human neuroblastoma cell line co-expressing APP
and TAU genes separated by IRES and designed for the screening of AD therapy drugs [69,70]. Using
the above test system, curcumin, its structural analogue demethoxycurcumin [69], and memantine
(non-competitive NMDA receptor antagonist (N-methyl-d-aspartate)) [70] have been able to inhibit
APP and TAU IRES-dependent translation initiation.
5. Multicistronic Vectors for Metabolic Disease Therapy
Metabolic diseases are characterized by the alteration of metabolic processes most often due
to the lack or deficiency of enzyme activity. The use of multicistronic vectors for the production
of insulin-producing cells has shown promising results in the development of new methods for
diabetes treatment [71]. Three transcription factors are required for insulin production—pancreatic and
duodenal homeobox-1 (Pdx1), neurogenin 3 (Ngn3), and v-musculoaponeurotic fibrosarcoma oncogene
homolog A (MafA). The transfection of hepatocytes with a multicistronic vector carrying the Pdx1,
Ngn3, and MafA genes has allowed the reprogramming of hepatocytes into insulin-producing cells
in vitro and correcting the diabetic state in vivo [32]. The use of insulin-producing induced pluripotent
stem cells (iPSCs) for the treatment of type I diabetes is also under investigation. To differentiate
iPSCs into insulin-producing cells, iPSCs were co-transduced with multicistronic adenoviral vectors
containing the Pdx1, Ngn3, or MafA genes linked through IRES to the green fluorescent protein (GFP)
reporter gene. The resulting insulin-producing cells were transplanted into the liver parenchyma
of type I diabetic mice, which resulted in hyperglycemia reversal [72]. The clinical manifestation of
the disease in some metabolic syndromes occurs only when enzyme activity significantly decreases;
often 5%–25% of the normal activity of the enzyme is sufficient to maintain the patient’s healthy
state [73,74]. One of these diseases is GM2-gangliosidosis (Tay-Sachs disease, Sandhoff disease, and
AB variant), which is a part of the group of lysosomal storage diseases caused by the accumulation of
GM2 gangliosides due to the deficiency of the β-hexosaminidase (Hex) enzyme. The accumulation of
GM2 gangliosides primarily affects CNS functions, resulting in severe neurodegeneration [74]. The use
of AAV9 encoding the genes of the α- and β-subunits of the HexA enzyme (HEXA and HEXB genes,
respectively) linked through P2A peptide sequence has been reported. The systemic administration of
this construct into a murine model with Sandhoff disease has increased animal survival rates by 56%,
due to the fact that the bicistronic construct provides maximum overexpression and secretion of the
HexA enzyme and AAV9 is able to overcome the blood–brain barrier [13].
The use of multicistronic vectors for the treatment of Fabry disease, an X-linked inherited disorder
characterized by the deficiency of the α-galactosidase A (a-Gal A) enzyme that leads to the impaired
metabolism of sphingolipids, has also been evaluated. The use of bicistronic retroviral vectors
expressing a-Gal A gene and drug-selectable multidrug resistance gene 1 (MDR1), which are separated
by the IRES sequence, has shown a significant increase in the activity of the missing a-Gal A enzyme in
cell culture in vitro [75].
The greatest success has been achieved in the treatment of mucopolysaccharidosis IIIA, a
progressive hereditary neurodegenerative disorder that manifests in early childhood. The disease is
caused by the mutations in the gene encoding heparan-N-sulfamidase and N-sulfoglycosamine
sulfohydrolase (SGSH) lysosomal enzymes, resulting in the accumulation of heparan sulfate.
Sulfatase-modifying factor (SUMF1) is an activator of the SGSH catalytic site. Studies in murine
models have shown that intraparenchymal administration of AAVrh.10-SGSH-IRES-SUMF1 improves
heparan sulfate catabolism and decreases microglia activation at injection sites, but no improvement
has been observed in areas of the brain distant from the injection site. Based on the obtained results,
phase I/II clinical trials were conducted, during which four children were intracerebrally injected with
AAVrh.10-SGSH-IRES-SUMF1. As a result, a cerebral atrophy was stopped in two of the four children,
and an improvement in behavior, attention, and sleep was observed in three patients [76].
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6. Multicistronic Vectors for the Treatment of Autoimmune Diseases
Autoimmune diseases are multifactorial disorders associated with the impairment of immune
system functions, including the abnormal regulation of cytokines, which are good targets for gene
therapy [77]. It is known that T-helper 17 (Th17) cells producing interleukin (IL)-17 play a key role
in inflammation initiation in autoimmune diseases, whereas IL-27 controls autoimmune diseases by
suppressing Th17 from producing IL-17. IL-27 also promotes the differentiation of T-cells that secrete
IL-10, which has anti-inflammatory properties. It has been suggested that IL-27 may serve as an
additional agent in the therapy of many autoimmune diseases. MSCs transduced with a lentivirus
encoding two IL-27 subunits (p28 and EBI3) linked through IRES have been used for cell-mediated
gene therapy of autoimmune diseases. It is worth noting that IRES-dependent expression of the EBI3
subunit was decreased by one third in comparison to p28 subunit expression, but this did not affect the
functionality of the resulting protein. However, the therapeutic effects of the construct have not been
evaluated [78].
Anti-inflammatory cytokine-based therapy may be a promising approach for the treatment of
multiple sclerosis, a chronic autoimmune disease in which demyelination of neurons in the CNS
occurs, which leads to neurological disabilities [79]. IL-4, leukemia inhibitory factor (LIF), and IL-10
are anti-inflammatory cytokines, whereas IL-17 is a pro-inflammatory cytokine [80–83]. It has been
suggested that inhibition of pro-inflammatory cytokines and overexpression of anti-inflammatory
cytokines may be an effective approach in the gene therapy of autoimmune diseases. A lentivirus
based on a multicistronic vector encoding IL-4, IL-10, and LIF through T2A and P2A peptide sequences
was used to modify Wharton’s jelly stem cells, the efficacy of which was further investigated in the
experimental model of mice with autoimmune encephalomyelitis. As a result, the damage in the brains
of a mouse model, the amount of IL-17, and cell infiltration in the brain were decreased in vivo [79].
7. Multicistronic Vectors for Cardiovascular Disease Therapy
Some studies have shown the efficacy of multicistronic vectors in the treatment of cardiovascular
diseases. For example, an IRES-based plasmid vector that encodes two angiogenic molecules, FGF2 and
the cysteine-rich angiogenic inducer 61 (Cyr61), has been found to be more effective in stimulating the
formation of a new vascular network in the hindlimb ischemia mouse model compared to monocistronic
construction, despite the fact that bicistronic vectors express a smaller amount of the corresponding
protein molecules than vectors encoding one gene [84]. This data indicate the possibility of increasing
therapy effectiveness, while reducing the side effects caused by the expression of a large amount of
one protein. A bicistronic IRES-based AAV vector encoding VEGF and bone morphogenetic protein
(BMP) genes was used for the genetic modification of rabbit bone marrow-derived mesenchymal
stem cells. The synergistic effect of the expression of two proteins with angiogenic and osteogenic
functions allowed the simultaneous stimulation of bone formation and vascular regeneration in the
rabbit hindlimb ischemia model in vivo [85]. Other IRES-based multicistronic vectors (VEGF-A/FGF4
and VEGF165/stromal cell-derived factor-1 (SDF-1)) have also been shown to be effective in therapy for
ischemia animal models in vivo [86,87].
Simultaneous equivalent expression of genes with a 2A peptide sequence-based vector encoding
transcription factors Gata4, Mef2c, and Tbx5, which are necessary for the in situ reprogramming of
cardiac fibroblasts in induced cardiomyocytes, has shown a higher efficacy in improving ventricular
function in mice after in vivo coronary ligation compared to monocistronic construction [18]. Clinical
trials of bicistronic plasmid encoding VEGF and FGF genes through IRES have shown plasmid safety,
improvement in tolerance to both physical activity and clinical symptoms, but not improvement
in myocardial perfusion [88]. However, the potential of multicistronic vectors for the treatment of
cardiovascular diseases remains largely unexplored.
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8. Multicistronic Vectors for Cancer Therapy
Since the etiology of cancer is fairly diverse, the treatment of cancer requires the development
of complex approaches, including immunotherapy, where the combination of various therapeutic
agents can significantly increase the effectiveness. One of the first examples of the use of multicistronic
constructs in cancer treatment was the production of an adenoviral vector encoding two subunits of
human IL-12 through IRES. The expressed cytokine has shown all biological activities of recombinant
human IL-12, such as the stimulation of proliferation of the activated natural killer (NK) and
T-cells, induction of the interferon-gamma (IFN-γ) secretion by NK and T-cells, and enhancement of
lymphokine-activated killer (LAK) activity [89]. There are other constructs simultaneously encoding
several cytokines [90,91]. For example, co-expression of IL-2 and tumor necrosis factor (TNF-α),
linked by IRES, in an oncolytic adenovirus genome, has allowed increases in the number of CD4+ and
CD8+ tumor-infiltrating lymphocytes, as well as T-helper 1 (Th1) and CD86+ dendritic cells (DCs)
in vivo [90,92]. Besides the immunomodulatory effect, higher direct antitumor activity can be achieved
by using IRES. For example, the combination of endostatin (ES) and herpes simplex virus thymidine
kinase (HSV-TK) suicidal genes has significantly inhibited cell proliferation and induced apoptosis
in C6 glioma cells compared to individual agents [93]. IRES-based multicistronic vectors containing
the combination of suicidal gene and immunomodulating cytokine have also been described. Such
combinations do not lead to a synergistic enhancement of the antitumor effect in vitro; however,
the direct immunomodulatory effect has not been evaluated [94]. Multicistronic vectors have also been
used to inhibit tumor lymphangiogenesis and angiogenesis. Thus, an adeno-associated vector with
fibstatin and platelet factor-4 variant 1 (CXCL4L1) genes has inhibited angiogenesis, lymphangiogenesis
and tumor spread to the lymph nodes in vivo [95].
The number of studies on the development of multicistronic structures with 2A peptide sequences
for cancer treatment is lower than with IRES, but judging by the number of publications in recent years,
this approach is also being actively studied. One of the first studies with 2A-peptide based vectors
was the production of the zaptuximab chimeric antibody, which binds to a receptor responsible for
selective induction of apoptosis in tumor cells. The lentiviral vector encoding zaptuximab heavy and
light chains through the F2A peptide sequence has been shown to induce apoptosis in various tumor
cell lines in vitro and in the mouse colon cancer model in vivo [96]. The F2A peptide was also used to
express anti-carcinoembryonic antigen (CEA)×anti-CD3 di-antibodies, and the assembly efficiency of
the antibodies was 3 times higher than IRES when using F2A, which led to an increase in T-cell cytotoxic
response against CEA-positive tumor cells [97]. The expression of yeast cytosine deaminase (yCD2)
from a retroviral genome through T2A has also been increased compared to IRES-based expression.
The use of the construction with the T2A peptide led to a higher survival rate of model mice with
intracranial tumors [59]. The assembly efficiency of IL-12 has also been increased by at least 2 times due
to the P2A peptide sequence compared with IRES, which led to a significant increase in CD8+ T-cell
number into the tumor environment and an increase in systemic anti-tumor response [98]. The use
of 2A peptides in cancer treatment so far is reduced due to an increase in the production of chimeric
antibodies or proteins consisting of several subunits. The prospect of combining various therapeutic
agents in one vector remains to be investigated.
9. Multicistronic Vectors for the Prevention of Viral and Bacterial Infections
The use of multicistronic vectors in the field of infectious diseases is mainly focused on the
development of preventive vaccines. Simultaneous co-expression of several viral antigens can provide
more effective immunization. For example, immunization of mice with a bicistronic vector expressing
two highly conserved antigens of influenza virus, nucleoprotein (NP) and matrix (M1), separated by
IRES has resulted in a full protection against the disease [99]. The same IRES-based strategy has been
used to create a vaccine against Staphylococcus aureus-induced mastitis [100], the immunization with
which has reduced the incidence of mastitis in cows. IRES has also been used to create antibodies
against staphylococcal enterotoxins (SEs), but its therapeutic effect has not been evaluated to date [101].
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IRES is also used to create vectors encoding antigens and an immunomodulating agent to modulate
immunogenicity. The use of a bicistronic vector encoding Hc gene of botulinum neurotoxin serotype A
(BoNT/A) and interleukin 4 (IL-4) gene via IRES has significantly increased the anti-AHc antibody
titers, serum neutralization titers, and survival rates of immunized mice [102].
The 2A peptide is also used to produce antiviral vaccines; for example, recombinant modified
vaccinia Ankara vector, encoding influenza A NP, M1, and PB1 protein genes, through P2A peptide
sequence has shown a complete protective effect when challenged with 2 LD50 of A/California/7/09
virus [103]. In general, the use of the strategy for creating multicistronic structures has not yet found a
wide distribution in the prevention and the treatment of infectious diseases. The number and published
data from existing investigations offer little hope for rapid development in this area in the near future.
10. Conclusions and Future Perspectives
IRES-based and 2A peptide-based vectors are promising tools that can be used in combined gene
therapy of many rare and/or heterogeneous diseases. The current number of studies investigating
multicistronic vectors is relatively small, but the data now available have shown the opportunities
available to combine therapeutic agents in order to increase effectiveness due to synergistic effects.
In addition, the clinical trials published to date have indicated the safety of the use of multicistronic
vectors in human therapy, which offers great opportunities for the development of new constructs.
However, to successfully use multicistronic vectors in the treatment of various diseases, it is necessary
to consider the major shortcomings of both IRES-based and 2A peptide sequence-based vectors, namely,
the relatively low expression of the second protein in the IRES-based constructs and the problems with
the polypeptide cleavage in 2A peptide-based constructs. Incomplete cleavage of products of 2A-based
multicistronic constructs can lead to a decreased yield of the final product and to the disruption of the
protein functions. Moreover, existing approaches to increase the efficiency of cleavage significantly
raise the efficiency, but still do not enable complete cleavage. In addition, the unequal expression of
proteins located in the different parts of the vector or separated with different 2A peptide sequences
forces us to pay more attention to the order of genes in multicistronic vectors in order to achieve more
significant therapeutic effects.
The use of multicistronic vectors has found the greatest success in the treatment of
neurodegenerative diseases. In particular, the experimental drug ProSavin, encoding AADC, TH,
and CH1 genes, separated by IRES, has shown safety and promising efficacy in the therapy of
PD patients in phase I/II clinical trials. Moreover, 2A-based multicistronic vectors can be used to
produce transgenic animals for modeling human AD. Encouraging results have also been obtained
in the treatment of metabolic diseases, particularly in the treatment of GM2-gangliosidoses and the
reprogramming of hepatocytes or iPSCs into insulin-producing cells for diabetes therapy. Moreover,
phase I/II clinical trials of IRES-based multicistronic constructs have shown the efficacy in the treatment
of mucopolysaccharidosis IIIA. The use of IRES- and 2A-based multicistronic vectors for the treatment
of cardiovascular diseases is limited to a small number of in vitro and in vivo studies. Therefore, it is
difficult to judge the development prospects of using multicistronic constructs in this field. This is not
the case with cancer therapy, where there are a large number of publications in recent years. Although
the use of IRES- and 2A-based multicistronic vectors in cancer therapy is currently limited to in vitro
and in vivo studies, and the use of 2A peptides is limited to the production of chimeric antibodies or
proteins consisting of several subunits, we believe that the number of investigations in this area will
continue to grow. In the field of infectious diseases, multicistronic constructs have so far found use only
in the production of preventive vaccines and progress in this area is not expected in the near future.
Multicistronic vector-based therapy has not yet revealed its potential and requires further research,
as well as the development of new approaches to increase the efficiency of cleavage in 2A-based
constructs. New developments in this area will significantly increase efficiency and expand the scope
of multicistronic structures in the therapy of various diseases.
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